Primary Immunodeficiency Clinical Trial
Official title:
A Multi-Center, Open-Label, Single-Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
Verified date | June 2020 |
Source | Grifols Therapeutics LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Approximately 60 subjects will be enrolled in order to have approximately 20 adult subjects and 20 pediatric subjects treated with subcutaneously administered Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%) who complete the entire study. This study will include 3 study stages: Screening/Previous Regimen Phase, IGSC 20% Treatment Stage 1 (13 IGSC 20% weekly doses), and IGSC 20% Treatment Stage 2 (39 IGSC 20% weekly doses). A total of 52 doses of IGSC 20% will be administered with a final follow-up visit 1 week after the last dose at Week 53. Subjects/caregivers will be trained on self-administration of IGSC 20% by the clinical site personnel.
Status | Completed |
Enrollment | 61 |
Est. completion date | May 15, 2019 |
Est. primary completion date | May 15, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Pre-existing diagnosis of PI with features of hypogammaglobulinemia requiring IgG replacement therapy - No serious bacterial infection within the 3 months prior to Screening and has no serious bacterial infections (SBIs) up to the time of the Baseline Visit - Currently on IgG replacement therapy (stable regimen [dose and dosing interval] via IV or SC infusion) for = 3 consecutive months at a dosage of at least 200 mg/kg per infusion - Documented (within previous 3 months) of an IgG trough level of = 500 mg/dL on current IgG replacement therapy regimen - Screening/pre-Baseline trough IgG levels must be = 500 mg/dL. Exclusion Criteria: - Known serious adverse reaction to immunoglobulin or any severe anaphylactic reaction to blood or any blood-derived product - History of blistering skin disease, clinically significant thrombocytopenia, bleeding disorder, diffuse rash, recurrent skin infections, or other disorders where SC therapy would be contraindicated during the study - Isolated IgG subclass deficiency, isolated specific antibody deficiency disorder, or transient hypogammaglobulinemia of infancy - Nephrotic syndrome, and/or a history of acute renal failure, and/or severe renal impairment, and/or is on dialysis - Known previous infection with or clinical signs and symptoms consistent with current hepatitis B virus or hepatitis C virus infection - History of (year prior to Screening or 2 episodes in lifetime) or current diagnosis of deep venous thrombosis or thromboembolism (e.g., myocardial infarction, cerebrovascular accident, or transient ischemic attack) - Acquired medical condition known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (absolute neutrophil count less than 1000/µL [1.0 x 10^9/L]), or human immunodeficiency virus infection/acquired immune deficiency syndrome - HIV positive by nucleic acid amplification technology based on a Screening blood sample - Uncontrolled arterial hypertension (adult subjects: systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg) - Receiving any of the following medications: (a) immunosuppressants including chemotherapeutic agents, (b) immunomodulators, (c) long-term systemic corticosteroids defined as daily dose > 1 mg of prednisone equivalent/kg/day for > 30 days Note: Intermittent courses of corticosteroids of not more than 10 days would not exclude a subject. Inhaled or topical corticosteroids are allowed. |
Country | Name | City | State |
---|---|---|---|
Australia | Wesley Medical Research | Auchenflower | |
Australia | Royal Melbourne Hospital | Parkville | |
Czechia | University Hospital | Hradec Kralove | |
France | CHU de Montpellier | Montpellier | |
Germany | Klinikum Dortmund gGmbH | Dortmund | |
Germany | Universitätsklinikum Hamburg-Eppendorf | Hamburg | |
Germany | Children's Hospital at Municipal Hospital St. Georg | Leipzig | |
Germany | University Hospital of Mainz | Mainz | |
Germany | Asklepios Klinik Sankt Augustin | Sankt Augustin | |
Hungary | United St Istvan and St Laszlo Hospital | Budapest | |
Hungary | Josa Andras County Hospital | Nyiregyháza | |
Poland | The Children's Memorial Health Institute | Warsaw | |
Spain | Hospital Universitari Sant Joan de Déu | Barcelona | |
Spain | Hospital Universitario Vall d'Hebron | Barcelona | |
Spain | Vall d'Hebron University Hospital | Barcelona | |
Spain | Hospital Universitario Reina Sofia | Cordoba | |
Spain | Hospital 12 Octubre | Madrid | |
Spain | Hospital Clinico San Carlos | Madrid | |
Spain | Hospital Virgen del Rocio | Sevilla | |
Sweden | Stockholm | Stockholm | |
United Kingdom | Addenbrooke's Hospital | Cambridge | |
United Kingdom | St Bartholomew's Hospital | London | |
United Kingdom | Derriford Hospital | Plymouth |
Lead Sponsor | Collaborator |
---|---|
Grifols Therapeutics LLC |
Australia, Czechia, France, Germany, Hungary, Poland, Spain, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Serious Bacterial Infection (SBI) Per Participant Per Year | The rate of SBI events per participant per year during IGSC 20% treatment was calculated as the total number of SBI events divided by the total duration of exposure in years across all participants. The 2-sided 98% confidence interval (CI) was determined from a generalized linear model for poisson regression for the log-transformed number of events with log-transformed duration of exposure in years as an offset variable. | IGSC 20% Treatment Stage 1: Week 1 to 13; IGSC 20% Treatment Stage 2: Week 14 to 53; IGSC 20% Overall: Week 1 to 53 | |
Secondary | Mean Trough Total IgG Concentration | Mean trough total IgG concentration during the previous regimen phase was calculated as the average of the trough concentrations at the previous IVIG (pIV)#1 and pIV#2 visits for participants entering the study on a previous IVIG regimen, or at the previous subcutaneous immune globulin (SCIG) (pSC)#1 and baseline/SC#1 visits for participants entering the study on a previous SCIG regimen. Mean trough total IgG concentration during the IGSC 20% phase was calculated as the average of all steady state trough concentrations measured during the IGSC 20% treatment stage 2 at the visits corresponding to Weeks 17, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 53. | Previous Regimen Phase: 2 timepoints pre-dose of pIV or pSC between Screening and Baseline (up to 8 weeks). IGSC 20% Phase: Pre-dose of IGSC 20% at Baseline (Week 1), Weeks 2, 5, 9, 13, 17, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Week 53 | |
Secondary | Rate of Infection of Any Kind Per Participant Per Year | The total number of infections of any kind (serious/non-serious including acute sinusitis, exacerbation of chronic sinusitis, acute otitis media, pneumonia, acute bronchitis, infectious diarrhea, etc.) as determined by the investigator were evaluated. The rate of infection events per participant per year during IGSC 20% treatment was calculated as the total number of infection events divided by the total duration of exposure in years across all participants. The 2-sided 95% CI was determined from a generalized linear model for poisson regression for the log-transformed number of events with log-transformed duration of exposure in years as an offset variable. | IGSC 20% Treatment Stage 1: Week 1 to 13; IGSC 20% Treatment Stage 2: Week 14 to 53; IGSC 20% Overall: Week 1 to 53 | |
Secondary | Rate of Days on Antibiotics Per Participants Per Year | The rate of days on antibiotics per participants per year during IGSC 20% treatment was calculated as the total number of days on antibiotic divided by the total duration of exposure in years across all participants. The 2-sided 95% CI was determined from a generalized linear model for poisson regression for the log transformed number of days with log-transformed duration of exposure in years as an offset variable. | IGSC 20% Treatment Stage 1: Week 1 to 13; IGSC 20% Treatment Stage 2: Week 14 to 53; IGSC 20% Overall: Week 1 to 53 | |
Secondary | Rate of Hospitalization Due to Infection Per Participants Per Year | The rate of hospitalization due to infection events per participant per year during IGSC 20% treatment was calculated as the total number of hospitalization due to infection events divided by the total duration of exposure in years across all participants. The 2-sided 95% CI was determined from a generalized linear model for poisson regression for the log-transformed number of events with log-transformed duration of exposure in years as an offset variable. | IGSC 20% Treatment Stage 1: Week 1 to 13; IGSC 20% Treatment Stage 2: Week 14 to 53; IGSC 20% Overall: Week 1 to 53 | |
Secondary | Rate of Days of Work/School/Daily Activities Missed Per Participants Per Year Due to Infections and Related Treatment | The rate of days of work, school or daily activities missed per participant per year during IGSC 20% treatment was calculated as the total number of days of work/school/daily activities missed divided by the total duration of exposure in years across all participants. The 2-sided 95% CI was determined from a generalized linear model for poisson regression for the log-transformed number of days with log transformed duration of exposure in years as an offset variable. | IGSC 20% Treatment Stage 1: Week 1 to 13; IGSC 20% Treatment Stage 2: Week 14 to 53; IGSC 20% Overall: Week 1 to 53 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04561115 -
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
|
Phase 3 | |
Recruiting |
NCT06355323 -
Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France
|
N/A | |
Completed |
NCT04566692 -
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
|
Phase 4 | |
Completed |
NCT01465958 -
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
|
Phase 4 | |
Completed |
NCT01581593 -
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
|
Phase 3 | |
Completed |
NCT02881437 -
IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
|
Phase 4 | |
Recruiting |
NCT06092528 -
Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT03576742 -
Severe Immune Cytopenia Registry Www.Sic-reg.Org
|
||
Completed |
NCT03907241 -
CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
|
Phase 3 | |
Not yet recruiting |
NCT04902807 -
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
|
||
Completed |
NCT03339778 -
The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations
|
N/A | |
Enrolling by invitation |
NCT00895271 -
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
|
||
Recruiting |
NCT03206099 -
NIAID Centralized Sequencing Protocol
|
||
Completed |
NCT02503293 -
A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
|
Phase 4 | |
Recruiting |
NCT03610802 -
Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
|
||
Completed |
NCT03815357 -
What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
|
||
Completed |
NCT02269163 -
Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
|
Phase 3 | |
Terminated |
NCT03733249 -
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02123615 -
ASIS for GAMMAGARD in Primary Immunodeficiency
|
Phase 1/Phase 2 | |
Completed |
NCT02604810 -
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
|
Phase 3 |